SCHEMBL156266

SCHEMBL156266

CCOC(=O)c1cc2ccc(Br)cc2s1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN2 P17706 2/20 0.55
MAPT P10636 5/20 0.48
GAA P10253 1/20 0.48
HDAC1 Q13547 3/20 0.47
HDAC3 O15379 2/20 0.47
HDAC4 P56524 2/20 0.47
HDAC6 Q9UBN7 2/20 0.47
HDAC7 Q8WUI4 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC10 Q969S8 1/20 0.47
HDAC11 Q96DB2 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC9 Q9UKV0 1/20 0.47
HDAC5 Q9UQL6 1/20 0.47
KDM4E B2RXH2 5/20 0.46
L3MBTL1 Q9Y468 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
TDP1 Q9NUW8 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3470329 0.88 LMNA (0.58) PTPN2MAPTGAAHDAC1HDAC3
SCHEMBL8250276 0.85 HDAC1 (0.60) PTPN2MAPTGAAHDAC1HDAC3
SCHEMBL31207824 0.84 HSD17B1 (0.51) PTPN2MAPTGAAHDAC1HDAC3
SCHEMBL1390384 0.84 HSD17B1 (0.51) PTPN2MAPTGAAHDAC1HDAC3
SCHEMBL155423 0.84 PTPN2 (0.50) PTPN2MAPTGAAHDAC1HDAC3
SCHEMBL29445391 0.83 HDAC1 (0.60) PTPN2MAPTHDAC1HDAC3HDAC4
SCHEMBL497904 0.83 HDAC1 (0.60) PTPN2MAPTHDAC1HDAC3HDAC4
SCHEMBL2238245 0.82 PTPN2 (0.60) PTPN2MAPTGAAHDAC1HDAC3
SCHEMBL2822973 0.82 PTPN2 (0.49) PTPN2MAPTGAAHDAC1HDAC3
SCHEMBL16595447 0.82 ALOX15 (0.51) PTPN2MAPTGAAHDAC1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12441724-B2 Inhibitors of plasma kallikrein and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-10-14 US disclosed
US-20250074902-A1 FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR SHANGHAI JINGXIN BIOMEDICAL CO., LTD. (CN) 2025-03-06 US disclosed
WO-2025002040-A1 CRYSTAL FORM OR SALT OF BICYCLIC HETEROARYL AMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 上海京新生物医药有限公司 2025-01-02 WO disclosed
EP-4458824-A1 FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR Shanghai Jingxin Biomedical Co., Ltd. (CN) 2024-11-06 EP disclosed
US-20240317774-A1 Pharmaceutical Compound GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2024-09-26 US disclosed
CN-118488951-A Fused bicyclic heteroaryl amide compounds as inhibitors of protein aggregation 上海京新生物医药有限公司 2024-08-13 CN disclosed
EP-4355750-A1 PHARMACEUTICAL COMPOUND GlaxoSmithKline Intellectual Property Development Limited (GB) 2024-04-24 EP disclosed
CN-117480172-A Pharmaceutical compounds 葛兰素史密斯克莱知识产权发展有限公司 2024-01-30 CN disclosed
WO-2023125376-A1 FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR 上海京新生物医药有限公司 2023-07-06 WO disclosed
WO-2023125376-A1 FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR 上海京新生物医药有限公司 2023-07-06 WO disclosed
WO-2007061978-A1 SPIROCYCLIC COMPOUNDS AS HDAC INHIBITORS MERCK & CO., INC. (US) 2007-05-31 WO disclosed
WO-2007061978-A1 SPIROCYCLIC COMPOUNDS AS HDAC INHIBITORS MERCK & CO., INC. (US) 2007-05-31 WO disclosed
US-20070117824-A1 Spirocyclic compounds MERCK SHARP & DOHME LLC 2007-05-24 US disclosed
US-20070117824-A1 Spirocyclic compounds MERCK SHARP & DOHME LLC 2007-05-24 US disclosed
US-20070117824-A1 Spirocyclic compounds MERCK SHARP & DOHME LLC 2007-05-24 US disclosed
WO-2006115835-A2 BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES MERCK & CO., INC. (US) 2006-11-02 WO disclosed
WO-2006115835-A2 BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES MERCK & CO., INC. (US) 2006-11-02 WO disclosed
WO-2006115845-A1 BENZOTHIOPHENE DERIVATIVES MERCK & CO., INC. (US) 2006-11-02 WO disclosed
WO-2006115845-A1 BENZOTHIOPHENE DERIVATIVES MERCK & CO., INC. (US) 2006-11-02 WO disclosed
US-20050233988-A1 Novel compounds TANABE SEIYAKU CO., LTD. (JP) 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050233988-A1 Novel compounds CYP1B1, CYP4B1, CYP2B6 PTPN2 3944/4885MAPT 3756/4885GAA 2394/4885
US-20250074902-A1 FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR HTT, PARK7, FUS PTPN2 4737/4885MAPT 9/4885GAA 1385/4885
US-12441724-B2 Inhibitors of plasma kallikrein and uses thereof KLKB1, KLK1, KLK5 PTPN2 2888/4885MAPT 2953/4885GAA 1581/4885
US-20240317774-A1 Pharmaceutical Compound ABCB11, MAN2B1, CYP11B2 PTPN2 2343/4885MAPT 1160/4885GAA 139/4885
US-20070117824-A1 Spirocyclic compounds BRDT, TXNRD3, HDAC1 PTPN2 434/4885MAPT 1986/4885GAA 2383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.